Hansoh's Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16
CompanyDrug

Hansoh’s Selective TYK2 Inhibitor HS‑10374 Hits Co‑Primary Endpoints in Pivotal Phase III Psoriasis Trial – Over Half of Patients Reach PASI 90 at Week 16

Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that HS‑10374, its in‑house‑developed selective allosteric inhibitor of tyrosine kinase 2 (TYK2), met co‑primary endpoints and multiple secondary endpoints in the pivotal…

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models
CompanyDeals

Insilico Medicine Strikes Tens‑of‑Millions‑of‑Dollars AI Collaboration with Frontier Foundation Model Lab – MMAI Gym Framework to Power Generative Biology Models

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented
Policy / Regulatory

NMPA Releases 109th RLD Catalog for Chemical Generics – 30 New Product Specifications Added, 24 Supplemented

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive
CompanyDeals

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

- Advertisement -
Ad image
APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboration
CompanyDeals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications
CompanyDeals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

CompanyDeals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China's Severe Pain Market
CompanyDeals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market
CompanyDeals

Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market

China NMPA Approves World's First Invasive BCI Medical Device – Brain-Computer Interface Hand Motor System Targets Spinal Cord Injury Patients
Medical Device

China NMPA Approves World’s First Invasive BCI Medical Device – Brain-Computer Interface Hand Motor System Targets Spinal Cord Injury Patients

CompanyDrug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Sino Biopharm's TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers
CompanyDrug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth
Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

CompanyDeals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

CompanyDrug

Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers

CompanyDrug

Hengrui’s SHR-2524 Wins NMPA Phase I Approval – Novel Subcutaneous Formulation Plus Bevacizumab Targets First-Line Liver Cancer

Show More